Catena Biosciences vs Revvity

Side-by-side comparison of AI visibility scores, market position, and capabilities

Revvity leads in AI visibility (94 vs 41)
Catena Biosciences logo

Catena Biosciences

EmergingHealthcare

General

US YC W21 protein conjugation technology for homogeneous ADCs and biologics at $9.1M total ($2.35M seed May 2024 LongeVC/Caffeinated) and $750K revenue Jun 2025; MPC platform competing with Ajinomoto and Abzena for precise ADC conjugation services.

AI VisibilityBeta
Overall Score
C41
Category Rank
#489 of 1158
AI Consensus
77%
Trend
up
Per Platform
ChatGPT
43
Perplexity
50
Gemini
48

About

Catena Biosciences is a United States-based biotechnology company — backed by Y Combinator (W21) with $9.1 million in total funding including a $2.35 million seed round in May 2024 from LongeVC, CA Innovation Fund, Civilization Ventures, Pioneer Fund, Freeflow Ventures, Caffeinated Capital, and BrightEdge Capital, plus NIH SBIR grants — developing next-generation protein conjugation technology that enables the rapid, selective attachment of functional payloads (drugs, labels, polymers, other proteins) to therapeutic proteins using natural amino acids as conjugation handles, generating $750,000 in annual revenue as of June 2025 and serving pharmaceutical companies and researchers developing antibody-drug conjugates (ADCs), bispecific antibodies, vaccine adjuvants, and next-generation protein therapeutics for autoimmune disorders, oncology, and infectious disease.

Full profile
Revvity logo

Revvity

LeaderHealthcare Tech

Life Science Tools & Diagnostics

Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.

AI VisibilityBeta
Overall Score
A94
Category Rank
#1 of 1
AI Consensus
72%
Trend
up
Per Platform
ChatGPT
92
Perplexity
99
Gemini
96

About

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.

Full profile

AI Visibility Head-to-Head

41
Overall Score
94
#489
Category Rank
#1
77
AI Consensus
72
up
Trend
up
43
ChatGPT
92
50
Perplexity
99
48
Gemini
96
51
Claude
89
43
Grok
88

Key Details

Category
General
Life Science Tools & Diagnostics
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Revvity
Life Science Tools & Diagnostics

Integrations

Only Revvity
Revvity is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.